Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2013, Article ID 786107, 5 pages
http://dx.doi.org/10.1155/2013/786107
Clinical Study

Is Spectral-Domain Optical Coherence Tomography Essential for Flexible Treatment Regimens with Ranibizumab for Neovascular Age-Related Macular Degeneration?

1Beyoglu Eye Training and Research Hospital, Bereketzade Camii Sok., Kuledibi, Beyoglu, 34421 Istanbul, Turkey
2Sisli Etfal Training and Research Hospital, 34360 Istanbul, Turkey
3Department of Ophthalmology, Medeniyet University, 34772 Istanbul, Turkey

Received 4 June 2013; Accepted 3 October 2013

Academic Editor: Veronica Castro Lima

Copyright © 2013 Abdullah Ozkaya et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L.-Y. Ngai, N. Stocks, J. M. Sparrow et al., “The prevalence and analysis of risk factors for age-related macular degeneration: 18-year follow-up data from the Speedwell eye study, United Kingdom,” Eye, vol. 25, no. 6, pp. 784–793, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Roy and M. Kaiser-Kupfer, “Second eye involvement in age-related macular degeneration: a four-year prospective study,” Eye, vol. 4, no. 6, pp. 813–818, 1990. View at Google Scholar · View at Scopus
  3. M. Votruba and Z. Gregor, “Neovascular age-related macular degeneration: present and future treatment options,” Eye, vol. 15, no. 3, pp. 424–429, 2001. View at Google Scholar · View at Scopus
  4. Macular Photocoagulation Study Group, “Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration: results of a randomized clinical trial,” Archives of Ophthalmology, vol. 109, no. 9, pp. 1220–1231, 1991. View at Google Scholar · View at Scopus
  5. L. Akduman, M. P. Karavellas, J. C. Macdonald, R. J. Olk, and W. R. Freeman, “Macular translocation with retinotomy and retinal rotation for exudative age-related macular degeneration,” Retina, vol. 19, no. 5, pp. 418–423, 1999. View at Google Scholar · View at Scopus
  6. G. S. Rubin and N. M. Bressler, “Effects of verteporfin therapy on contrast on sensitivity: results from the treatment of age-related macular degeneration with photodynamic therapy (TAP) investigation-TAP report No 4,” Retina, vol. 22, no. 35, pp. 536–544, 2002. View at Google Scholar
  7. A. Özkaya, Z. Gürcan, U. Yiğit, Ö. Elmastaş Gültekin, and H. M. Özkaya, “Photodynamic therapy results in age related macular degeneration,” Retina and Vitreous, vol. 4, no. 1, pp. 289–296, 2010. View at Google Scholar
  8. J. L. Kovach, S. G. Schwartz, H. W. Flynn Jr., and I. U. Scott, “Anti-VEGF treatment strategies for wet AMD,” Journal of Ophthalmology, vol. 2012, Article ID 786870, 7 pages, 2012. View at Publisher · View at Google Scholar
  9. D. M. Brown, P. K. Kaiser, M. Michels et al., “Ranibizumab versus verteporfin for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 355, no. 14, pp. 1432–1444, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. P. J. Rosenfeld, D. M. Brown, J. S. Heier et al., “Ranibizumab for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 355, no. 14, pp. 1419–1431, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. G. A. Lalwani, P. J. Rosenfeld, A. E. Fung et al., “A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study,” American Journal of Ophthalmology, vol. 148, no. 1, pp. 43–58, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. U. Schmidt-Erfurth, B. Eldem, R. Guymer et al., “Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study,” Ophthalmology, vol. 118, no. 5, pp. 831–839, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. D. F. Martin, M. G. Maguire, G. Ying, J. E. Grunwald, S. L. Fine, and G. J. Jaffe, “Ranibizumab and bevacizumab for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 364, no. 20, pp. 1897–1908, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Monés, M. Biarnés, F. Trindade, and R. Casaroli-Marano, “FUSION regimen: ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and relatively good baseline visual acuity,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 250, no. 12, pp. 1737–1744, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. I. Zampros, A. Praidou, P. Brazitikos, P. Ekonomidis, and S. Androudi, “Antivascular endothelial growth factor agents for neovascular age-related macular degeneration,” Journal of Ophthalmology, vol. 2012, Article ID 319728, 12 pages, 2012. View at Publisher · View at Google Scholar
  16. S. M. Hariprasad, L. S. Morse, H. Shapiro, P. Wong, and L. Tuomi, “Fixed monthly versus less frequent ranibizumab dosing and predictors of visual response in exudative age-related macular degeneration,” Journal of Ophthalmology, vol. 2012, Article ID 690641, 8 pages, 2012. View at Publisher · View at Google Scholar
  17. M. Kakinoki, T. Miyake, O. Sawada, T. Sawada, H. Kawamura, and M. Ohji, “Comparison of macular thickness in diabetic macular edema using spectral-domain optical coherence tomography and time-domain optical coherence tomography,” Journal of Ophthalmology, vol. 2012, Article ID 959721, 5 pages, 2012. View at Publisher · View at Google Scholar
  18. E. Hatef, A. Khwaja, Z. Rentiya et al., “Comparison of time domain and spectral domain optical coherence tomography in measurement of macular thickness in macular edema secondary to diabetic retinopathy and retinal vein occlusion,” Journal of Ophthalmology, vol. 2012, Article ID 354783, 9 pages, 2012. View at Publisher · View at Google Scholar
  19. U. Eriksson, A. Alm, and E. Larsson, “Is quantitative spectral-domain superior to time-domain optical coherence tomography (OCT) in eyes with age-related macular degeneration?” Acta Ophthalmologica, vol. 90, no. 7, pp. 620–627, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. I. Krebs, S. Hagen, E. Smretschnig, I. Womastek, W. Brannath, and S. Binder, “Conversion of stratus optical coherence tomography (OCT) retinal thickness to cirrus OCT values in age-related macular degeneration,” British Journal of Ophthalmology, vol. 95, no. 11, pp. 1552–1554, 2012. View at Google Scholar · View at Scopus
  21. D. M. Luviano, M. S. Benz, R. Y. Kim et al., “Selected clinical comparisons of spectral domain and time domain optical coherence tomography,” Ophthalmic Surgery Lasers and Imaging, vol. 40, no. 3, pp. 325–328, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. G. Querques, R. Forte, E. Berboucha et al., “Spectral-domain versus time domain optical coherence tomography before and after ranibizumab for age-related macular degeneration,” Ophthalmic Research, vol. 46, no. 3, pp. 152–159, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Cukras, Y. D. Wang, C. B. Meyerle, F. Forooghian, E. Y. Chew, and W. T. Wong, “Optical coherence tomography-based decision making in exudative age-related macular degeneration: comparison of time- vs spectral-domain devices,” Eye, vol. 24, no. 5, pp. 775–783, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Sayanagi, S. Sharma, T. Yamamoto, and P. K. Kaiser, “'Comparison of spectral-domain versus time-domain optical coherence tomography in management of age-related macular degeneration with ranibizumab,” Ophthalmology, vol. 116, no. 5, pp. 947–955, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. P. S. Muether, M. M. Hermann, K. Koch, and S. Fauser, “Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 249, no. 5, pp. 633–637, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Arias, F. Armadá, J. Donate et al., “Delay in treating age-related macular degeneration in Spain is associated with progressive vision loss,” Eye, vol. 23, no. 2, pp. 326–333, 2008. View at Google Scholar · View at Scopus
  27. T. Baba, M. Kitahashi, M. Kubota-Taniai, T. Oshitari, and S. Yamamoto, “Two-year course of subfoveal pigment epithelial detachment in eyes with age-related macular degeneration and visual acuity better than 20/40,” Ophthalmologica, vol. 228, no. 2, pp. 102–109, 2012. View at Google Scholar
  28. A. Mariani, A. Deli, A. Ambresin, and I. Mantel, “Characteristics of eyes with secondary loss of visual acuity receiving variable dosing ranibizumab for neovascular age-related macular degeneration,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 249, no. 11, pp. 1635–1642, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. H. Gerding, V. Loukopoulos, J. Riese, L. Hefner, and M. Timmermann, “Results of flexible ranibizumab treatment in age-related macular degeneration and search for parameters with impact on outcome,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 249, no. 5, pp. 653–662, 2011. View at Publisher · View at Google Scholar · View at Scopus